| Literature DB >> 35933357 |
Yiqing Ling1, Zhenyu Shi1, Chenying Su2, Xiaochen Liu3, Lingxin Zheng4, Xiaohao Pan4, Yan Sun4, Xuan Zhang4, Jinling Wei5, Ju Li1, Peijian Tong1, Taotao Xu6.
Abstract
BACKGROUND: Cerebral infarction (CI) is an unusual complication in patients with bleeding disorders. To our knowledge, this is the first case of postoperative internal border-zone infarction (I-BZI) from Hemophilia A. CASEEntities:
Keywords: Case report; Cerebral infarction; Factor VIII deficiency; Hemophilia A; Hemophilic pseudotumor
Mesh:
Year: 2022 PMID: 35933357 PMCID: PMC9357307 DOI: 10.1186/s12893-022-01753-2
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Fig. 1Preoperative photograph of left thigh showing a giant mass on the anterolateral region of left thigh (A). Anteroposterior radiograph of the left thigh showing a giant soft-tissue mass located at the left thigh without periosteal reaction of femur shaft (B). Coronal and axial Magnetic resonance imaging (MRI) of the left thigh showing the large pseudotumor masses on the anterolateral region of left thigh (C, D). Axial computerized tomography of leg showed intramuscular hematoma in left thigh (E–H). Diffusion weighted MRI and T2 weighted MRI of the brain showed there were multiple acute cerebral infarctions in bilateral lateral ventricles (internal border zone) and multiple ischemic foci in the white matter areas and basal ganglia of the bilateral cerebral hemispheres (I–L)
Summary of laboratory analysis and coagulation factor administration at different time point in this study
| Date | Hemoglobin (g/L) | Platelet (109/L) | FVIII activity (%) | APTT (s) | D-dimer (mg/L FEU) | FIB (g/L) | Blood pressure (mmHg) | Volume of coagulation factor administration |
|---|---|---|---|---|---|---|---|---|
| 01/26/2021 (on admission) | 137 | 204 | 1.5 | 71.50 | 3.33 | 3.11 | 145/96 | – |
| 01/28/2021 (prior to surgery) | – | 223 | 50.4 | 43.90 | 4.48 | 2.94 | 112/63 | Bolus dose of 3500 IU + 1000 IU |
| 01/29/2021 (POD1) | 83 | 180 | 29.8 | 47.10 | 1.06 | 2.74 | 134/75 | Maintenance dose of 2000 IU q8h |
| 01/30/2021 (POD2: patient with slurred speech and decreased responsiveness) | 54 | 173 | 17.7 | 52.70 | 0.71 | 4.77 | 110/70 | Bolus dose of 4000 IU and maintenance dose of 4000 IU q8h |
| 01/30/2021 (after intravenous injection with RBC 2U and plasma 390 ml) | 62 | 176 | 43.5 | 40.60 | 0.66 | 4.53 | 115/72 | Maintenance dose of 4000 IU q8h |
| 01/31/2021 (POD4: patient with worsening alteration of consciousness) | 47 | 157 | 76.0 | 46.40 | 0.66 | 3.83 | 120/70 | Maintenance dose of 4000 IU q8h |
| 01/31/2021 (after intravenous injection with RBC 3U and plasma 350 ml) | 73 | 213 | 96.2 | 38.90 | 0.46 | 6.65 | 140/80 | Maintenance dose of 4000 IU q8h |